"MI Responds" features real-time commentary from Manhattan Institute scholars on breaking news and developing issues. Click here to view more.
The President’s Precision Medicine Initiative has the potential to be his most significant health care legacy, helping to develop tailored health solutions to millions of Americans.
But much of it will depend on the policies of his successor: and both Secretary Clinton and Donald Trump have called for price controls on new medicines. If we don’t encourage companies to make the large, long-term investments needed to develop precision medicines, sharing data and building databases won’t be enough to deliver new cures.
Paul Howard is a senior fellow and director of health policy at the Manhattan Institute